MX353476B - Anticuerpos anti-cxcl13 y metodos para usarlos. - Google Patents

Anticuerpos anti-cxcl13 y metodos para usarlos.

Info

Publication number
MX353476B
MX353476B MX2013002495A MX2013002495A MX353476B MX 353476 B MX353476 B MX 353476B MX 2013002495 A MX2013002495 A MX 2013002495A MX 2013002495 A MX2013002495 A MX 2013002495A MX 353476 B MX353476 B MX 353476B
Authority
MX
Mexico
Prior art keywords
methods
cxcl13
same
cxcl13 antibodies
antibodies
Prior art date
Application number
MX2013002495A
Other languages
English (en)
Spanish (es)
Other versions
MX2013002495A (es
Inventor
S Smith Ernest
Klimatcheva Ekaterina
Paris Mark
Original Assignee
Vaccinex Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc Star filed Critical Vaccinex Inc Star
Publication of MX2013002495A publication Critical patent/MX2013002495A/es
Publication of MX353476B publication Critical patent/MX353476B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013002495A 2010-09-02 2011-09-01 Anticuerpos anti-cxcl13 y metodos para usarlos. MX353476B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37967210P 2010-09-02 2010-09-02
US201161481645P 2011-05-02 2011-05-02
PCT/US2011/050177 WO2012031099A2 (en) 2010-09-02 2011-09-01 Anti-cxcl13 antibodies and methods of using the same

Publications (2)

Publication Number Publication Date
MX2013002495A MX2013002495A (es) 2013-06-05
MX353476B true MX353476B (es) 2018-01-15

Family

ID=45773520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002495A MX353476B (es) 2010-09-02 2011-09-01 Anticuerpos anti-cxcl13 y metodos para usarlos.

Country Status (13)

Country Link
US (3) US9963504B2 (OSRAM)
EP (1) EP2611832B1 (OSRAM)
JP (2) JP6097690B2 (OSRAM)
KR (1) KR101862236B1 (OSRAM)
CN (1) CN103347896B (OSRAM)
AU (1) AU2011295902B2 (OSRAM)
BR (1) BR112013005145B1 (OSRAM)
CA (1) CA2810217C (OSRAM)
DK (1) DK2611832T3 (OSRAM)
MX (1) MX353476B (OSRAM)
NZ (1) NZ608318A (OSRAM)
SG (1) SG188285A1 (OSRAM)
WO (1) WO2012031099A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011718A (es) 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2012082494A2 (en) 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
DK2766093T3 (en) 2011-10-11 2018-06-06 Vaccinex Inc USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER
KR102090969B1 (ko) * 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
WO2014003742A1 (en) * 2012-06-27 2014-01-03 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
CN104884955B (zh) * 2012-12-07 2017-06-27 巴克斯特国际公司 抗‑mif抗体的细胞迁移测定方法
JP6363623B2 (ja) * 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法
BR112015021964A2 (pt) * 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
SG11201808554TA (en) 2016-04-22 2018-11-29 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
JP7654548B2 (ja) * 2018-09-17 2025-04-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗ｋｌｒｇ１抗体
KR20200106056A (ko) * 2018-09-18 2020-09-10 아이-맵 바이오파마 유에스 리미티드 자가면역 질환 및 암을 치료하기 위한 항-cxcl13 항체
JP7748728B2 (ja) * 2020-06-11 2025-10-03 インペリアル・カレッジ・イノベーションズ・リミテッド 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
CN115975946A (zh) * 2022-12-01 2023-04-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 表达趋化因子cxcl10、cxcl13、ccl19的免疫细胞及其制备方法与应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6692920B1 (en) 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH11507224A (ja) 1995-06-05 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトケモカインβ−１１およびヒトケモカインα−１
WO1998011226A2 (en) 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001250412A1 (en) 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
CA2430401A1 (en) 2000-12-01 2002-06-06 Schering Corporation Uses of mammalian genes and related reagents
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20060054174A (ko) 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
EP1570857A1 (en) 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof
CA2563396A1 (en) * 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
BRPI0506125B8 (pt) 2004-07-09 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
WO2006113665A2 (en) * 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
KR101484025B1 (ko) * 2006-04-21 2015-01-19 얀센 바이오테크 인코포레이티드 염증성 질환의 치료를 위한 ｃｘｃｌ１３ 길항제 및 이의 용도
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) * 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
CA2682666A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20110300167A1 (en) 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
KR102090969B1 (ko) 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法
BR112015021964A2 (pt) 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos

Also Published As

Publication number Publication date
EP2611832B1 (en) 2017-11-29
US20150050287A9 (en) 2015-02-19
EP2611832A2 (en) 2013-07-10
WO2012031099A3 (en) 2012-06-07
JP2013539369A (ja) 2013-10-24
SG188285A1 (en) 2013-04-30
KR101862236B1 (ko) 2018-05-29
JP6097690B2 (ja) 2017-03-15
US10829550B2 (en) 2020-11-10
CA2810217C (en) 2019-03-12
CN103347896B (zh) 2017-06-13
CN103347896A (zh) 2013-10-09
US20210087263A1 (en) 2021-03-25
WO2012031099A9 (en) 2012-08-30
US9963504B2 (en) 2018-05-08
AU2011295902A1 (en) 2013-04-11
MX2013002495A (es) 2013-06-05
KR20130101046A (ko) 2013-09-12
CA2810217A1 (en) 2012-03-08
US20180244764A1 (en) 2018-08-30
NZ608318A (en) 2015-03-27
BR112013005145B1 (pt) 2022-02-15
US11981730B2 (en) 2024-05-14
WO2012031099A2 (en) 2012-03-08
EP2611832A4 (en) 2014-03-05
US20140147447A1 (en) 2014-05-29
AU2011295902B2 (en) 2014-12-04
BR112013005145A2 (pt) 2016-05-10
JP2017099379A (ja) 2017-06-08
DK2611832T3 (en) 2018-02-26

Similar Documents

Publication Publication Date Title
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
WO2010129917A3 (en) Anti-cd100 antibodies and methods for using the same
IN2014MN01879A (OSRAM)
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MX2013011385A (es) Moleculas de union a cd37 y sus inmunoconjugados.
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
PH12013500810B1 (en) Anti-il-23 antibodies
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
PH12014501427A1 (en) Anti-php-tau antibodies and their uses
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
SG195072A1 (en) Cd3-binding molecules capable of binding to human and non-human cd3
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
MX347164B (es) Anticuerpos anti-il-36r.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
GB201109238D0 (en) Antibodies
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2014014443A (es) Agentes de ligacion a tlr3.
AR123070A2 (es) Anticuerpos anti-il-23

Legal Events

Date Code Title Description
FG Grant or registration